Jump to content

Yttrium (90Y) clivatuzumab tetraxetan

From Wikipedia, the free encyclopedia
(Redirected from Clivatuzumab tetraxetan)
Yttrium (90Y) clivatuzumab tetraxetan
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetMUC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6496H9952N1716O2014S44
Molar mass145723.71 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer.[1] The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

The drug was developed by Immunomedics, Inc.

In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival.[3]

References

[edit]
  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical Association.
  2. ^ WHO Drug Information
  3. ^ Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer. March 2016